These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23648278)

  • 1. Nonlinear system identification for prostate cancer and optimality of intermittent androgen suppression therapy.
    Suzuki T; Aihara K
    Math Biosci; 2013 Sep; 245(1):40-8. PubMed ID: 23648278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piecewise affine systems modelling for optimizing hormone therapy of prostate cancer.
    Suzuki T; Bruchovsky N; Aihara K
    Philos Trans A Math Phys Eng Sci; 2010 Nov; 368(1930):5045-59. PubMed ID: 20921011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer.
    Shimada T; Aihara K
    Math Biosci; 2008; 214(1-2):134-9. PubMed ID: 18420226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new protocol for intermittent androgen suppression therapy of prostate cancer with unstable saddle-point dynamics.
    Suzuki Y; Sakai D; Nomura T; Hirata Y; Aihara K
    J Theor Biol; 2014 Jun; 350():1-16. PubMed ID: 24524858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent complete androgen blockade in metastatic prostate cancer.
    Rambeaud JJ
    Eur Urol; 1999; 35 Suppl 1():32-6. PubMed ID: 10081701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer.
    Salonen AJ; Taari K; Ala-Opas M; Viitanen J; Lundstedt S; Tammela TL;
    J Urol; 2012 Jun; 187(6):2074-81. PubMed ID: 22498230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study changes how physicians treat metastatic prostate cancer: intermittent hormone therapy not as effective as continuous hormone therapy, authors say.
    Printz C
    Cancer; 2013 Sep; 119(17):3103-4. PubMed ID: 24037668
    [No Abstract]   [Full Text] [Related]  

  • 8. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
    Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
    J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
    Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome.
    Malone S; Perry G; Eapen L; Segal R; Gallant V; Dahrouge S; Crook J; Spaans JN
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):699-706. PubMed ID: 17379438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent androgen deprivation therapy may prolong the duration of androgen dependence of well-differentiated prostate cancer.
    Kaneko Y; Maekawa S; Arakaki R; Okada Y; Terada N; Nishimura K
    Hinyokika Kiyo; 2006 Apr; 52(4):259-64. PubMed ID: 16686352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical modelling of prostate cancer growth and its application to hormone therapy.
    Tanaka G; Hirata Y; Goldenberg SL; Bruchovsky N; Aihara K
    Philos Trans A Math Phys Eng Sci; 2010 Nov; 368(1930):5029-44. PubMed ID: 20921010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.
    Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F
    Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer.
    Hirata Y; Bruchovsky N; Aihara K
    J Theor Biol; 2010 May; 264(2):517-27. PubMed ID: 20176032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer.
    Shulman MJ; Karam JA; Benaim EA
    Urology; 2004 Apr; 63(4):732-6. PubMed ID: 15072890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent androgen deprivation in advanced prostate cancer.
    de Reijke TM
    Urol Res; 1997; 25 Suppl 2():S63-6. PubMed ID: 9144889
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 20. A nonlinear competitive model of the prostate tumor growth under intermittent androgen suppression.
    Yang J; Zhao TJ; Yuan CQ; Xie JH; Hao FF
    J Theor Biol; 2016 Sep; 404():66-72. PubMed ID: 27259386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.